About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 3NCT01370005

12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus

This trial will evaluate safety and efficacy of BI 10773 in hypertensive patients with type 2 diabetes. Since hyperglycaemia and hypertension are key risk factors for both micro- and macrovascular com...

Lead sponsor: Boehringer Ingelheim•35 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Boehringer Ingelheim

Collaborators

Eli Lilly and Company

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. Patients \>=18 years with type 2 diabetes
•2. HbA1c of \>= 7.0% (53 mmol/mol) and =\< 10% (86 mmol/mol)
•3. Mean seated systolic blood pressure 130-159 mmHg and diastolic blood pressure 80-99 mmHg

Exclusion Criteria

•1. Uncontrolled hyperglycaemia with a glucose level \>240 mg/dl (\>13.3 mmol/L) after an overnight fast before randomization
•2. Known or suspected secondary hypertension
•3. Acute coronary syndrome (non-STEMI, STEMI and unstable angina pectoris), stroke or transient ischemic attack within 3 months prior to informed consent

Related studies

RECRUITINGPhase 3

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

NCT07218029 · Pulmonary Arterial Hypertension

RECRUITINGPhase 3

An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)

NCT07365332 · Pulmonary Arterial Hypertension

Natural History of Noncirrhotic Portal Hypertension

NCT02417740 · Cystic Fibrosis, Immunologic Deficiency Syndrome, and more

RECRUITINGPhase 1/2

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

NCT06649110 · Healthy Volunteers, Pulmonary Arterial Hypertension

Digital Solutions to Reduce Maternal Morbidity and Mortality in Pregnant Refugee Women

NCT06647511 · Gestational Hypertension

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: February 22, 2016Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE3

Enrollment825

Start dateJun 2011

Last updatedFeb 22, 2016

Condition

Diabetes Mellitus, Type 2 Hypertension

Locations shown

1245.48.10024 Boehringer Ingelheim Investigational Site

Huntsville, Alabama

1245.48.10002 Boehringer Ingelheim Investigational Site

Phoenix, Arizona

1245.48.10014 Boehringer Ingelheim Investigational Site

Lincoln, California

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 22, 2016Data synced to Clareo: May 17, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions